Completed

Eprex for Anemia in AIDS Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Epoetin alfa

Drug
Who is being recruted

Blood-Borne Infections+17

+ Urogenital Diseases

+ Genital Diseases

Over 12 Years
+10 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
See protocol details

Summary

Principal SponsorR W Johnson Pharmaceutical Research Institute
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

This study focuses on helping AIDS patients who are also dealing with anemia, a condition that causes a low red blood cell count. The main goal is to treat this anemia using a medication called Eprex, also known as erythropoietin. This research is important because it aims to improve the quality of life for AIDS patients who often experience fatigue and weakness due to anemia. In this treatment program, participants receive Eprex. This medication works by stimulating the body to produce more red blood cells, which can help alleviate anemia. The study measures how well the treatment works by monitoring changes in the participants' red blood cell counts. It's important to note that while this study offers potential benefits, it may also come with risks associated with any medical treatment.

NCT00002022
Principal SponsorR W Johnson Pharmaceutical Research Institute
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 12 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesHematologic DiseasesHemic and Lymphatic DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsCytopeniaAcquired Immunodeficiency SyndromeAnemiaHIV Infections

Criteria

5 inclusion criteria required to participate
> Grade 4 performance score
A clinical diagnosis of AIDS
A life expectancy = or > 3 months
Endogenous serum erythropoietin level = or < 500 U/ml
Show More Criteria
5 exclusion criteria prevent from participating
= or < grade 4 performance score
AIDS-related dementia
Acute symptomatic opportunistic infection or other AIDS-defining illness
Life expectancy < 3 months
Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

R W Johnson Pharmaceutical Research Institute

Raritan, United StatesOpen R W Johnson Pharmaceutical Research Institute in Google Maps
CompletedOne Study Center